Dexcom Continuous Glucose Monitoring (CGM) is proven to lower A1C and increase time in range.1-3,5,6 Dexcom ranks #1 in patient satisfaction,† adherence, and retention.7-9,‡
Company Background
Dexcom, Inc. empowers people to take control of health through innovative CGM systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
Product Overview
Dexcom G7 is the simple CGM for effortless diabetes management. Users will receive real-time glucose readings automatically on their compatible smart device§ or Dexcom receiver, no fingersticks|| required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels with a predictive low alert that can recognize potentially dangerous hypoglycemic incidents before they occur.
Dexcom CGM has demonstrated a >1% A1C reduction after 12 weeks.1,2,5 Dexcom G7 can help patients reach their glycemic goals and improve their quality of life.1-5,10 Dexcom G7 is a preferred CGM of national payors on the pharmacy benefit.7,¶ As the most covered CGM brand,7,# Dexcom requires only one prescription for Dexcom G7 to be sent directly to the pharmacy for a quick, simple start and low outof- pocket costs. Most covered patients pay $20 or less per month for Dexcom CGM.11,**
Dexcom G7 is an integrated CGM (iCGM) indicated for the widest age range and across diabetes types (type 1, type 2, and gestational diabetes) and treatment types (basal insulin, noninsulin, glucagon-like peptide-1). No other CGM system is more affordable than Dexcom G7 for Medicare patients.†† For more information on affordability programs, please visit dexcom.com/savings.
Features & Options
Dexcom G7 is the most connected CGM system7:
- The first and only iCGM brand that allows for Share and Follow while also using an automated insulin delivery (AID)-connected system.‡‡
- The first and only CGM with no fingersticks from day 1.||
- Only CGM with app features that help protect from severe hypoglycemia and diabetic ketoacidosis.12
- 1.7 million customer years and growing of powering AID systems.7
- Dexcom G7 is the most connected CGM,7 connecting to Tandem, Lily Tempo, Insulet Omnipod, and Beta Bionics devices.
Testimonials
Dexcom is the most affordable CGM brand at the pharmacy11,§§:
- Dexcom is the #1 recommended CGM system by patients.13,†
- 96% of patients say Dexcom G7 is easy to use.14
- Dexcom ranks #1 in patient satisfaction,† adherence, and retention.7-9,‡
- Dexcom is a preferred CGM of national payors on the pharmacy benefit.7,¶
- 98% of people have coverage for Dexcom G7.7,§§ ,||||
- 75% of Medicare Advantage lives have coverage for Dexcom G7 at the pharmacy.11 Savings programs are available for patients without CGM coverage.
Ordering Information
To order, please contact your pharmacy wholesale partner. Dexcom G7 is available to order from all major wholesalers.
*Compared to self-monitoring of blood glucose.
†Based on a comparison in net promoter scores across major CGM brands.
‡IQVIA paid sensor claims at 12 months.
§Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility.
|| Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
¶Individual coverage may vary depending on commercial pharmacy coverage benefits.
Individual coverage may vary depending on insurance plan.
** Individual pricing may vary depending on insurance coverage. IQVIA FIA retail data, paid sensor claims.
†† Under Medicare’s durable medical equipment (DME) fee schedule, reimbursement and coinsurance for
CGM using Current Procedural Terminology (CPT) codes A4239 and E2103 are the same, regardless of CGM brand.
‡‡ Internet connection and separate Follow app required. To view compatibility, visit dexcom.com/compatibility.
§§Individual pricing may vary depending on insurance coverage.
||||Includes both pharmacy and medical benefit.
1 Beck RW, et al. JAMA. 2017;317(4):371-378. 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272. 4 Laffel LM, et al. JAMA. 2020;323(23):2388-5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 6 Garg SK, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39. 11 Dexcom, data on file, 2025. 12 Graham R, et al. Diabetes Technol Ther. 2024;26(1):24-32. 13 Seagrove Patient Survey 2024. 14 Dexcom G7 CGM System User Guide.
